Cecilia Olsson Ladjevardi
PhD student at Department of Immunology, Genetics and Pathology; Research programme: Cancer Immunotherapy; Research group Gustav Ullenhag
- E-mail:
- cecilia.olsson.ladjevardi@igp.uu.se
- Visiting address:
- Akademiska sjukhuset, ingång 100/101
751 85 Uppsala - Postal address:
- Akademiska sjukhuset, ingång 100/101
751 85 Uppsala
Resident physician at Department of Immunology, Genetics and Pathology; Clinical units; Clinical oncology
- E-mail:
- cecilia.olsson.ladjevardi@igp.uu.se
- Visiting address:
- Akademiska sjukhuset, ingång 100/101
751 85 Uppsala - Postal address:
- Akademiska sjukhuset, ingång 100/101
751 85 Uppsala
Publications
Recent publications
Part of Cancer Immunology and Immunotherapy, 2025
- DOI for Differences in immune-related toxicity between PD-1 and PD-L1 inhibitors: a retrospective cohort study in patients with advanced cancer
- Download full text (pdf) of Differences in immune-related toxicity between PD-1 and PD-L1 inhibitors: a retrospective cohort study in patients with advanced cancer
Part of Frontiers in Oncology, 2024
- DOI for Multiple immune-related adverse events secondary to checkpoint inhibitor therapy in patients with advanced cancer: association with treatment effectiveness
- Download full text (pdf) of Multiple immune-related adverse events secondary to checkpoint inhibitor therapy in patients with advanced cancer: association with treatment effectiveness
Part of Pigment Cell & Melanoma Research, 2024
- DOI for The role of dacarbazine and temozolomide therapy after treatment with immune checkpoint inhibitors in malignant melanoma patients: A case series and meta-analysis
- Download full text (pdf) of The role of dacarbazine and temozolomide therapy after treatment with immune checkpoint inhibitors in malignant melanoma patients: A case series and meta-analysis
Part of Cancer Medicine, p. 13217-13224, 2023
- DOI for Predicting immune-related adverse events using a simplified frailty score in cancer patients treated with checkpoint inhibitors: A retrospective cohort study
- Download full text (pdf) of Predicting immune-related adverse events using a simplified frailty score in cancer patients treated with checkpoint inhibitors: A retrospective cohort study
All publications
Articles in journal
Part of Cancer Immunology and Immunotherapy, 2025
- DOI for Differences in immune-related toxicity between PD-1 and PD-L1 inhibitors: a retrospective cohort study in patients with advanced cancer
- Download full text (pdf) of Differences in immune-related toxicity between PD-1 and PD-L1 inhibitors: a retrospective cohort study in patients with advanced cancer
Part of Frontiers in Oncology, 2024
- DOI for Multiple immune-related adverse events secondary to checkpoint inhibitor therapy in patients with advanced cancer: association with treatment effectiveness
- Download full text (pdf) of Multiple immune-related adverse events secondary to checkpoint inhibitor therapy in patients with advanced cancer: association with treatment effectiveness
Part of Pigment Cell & Melanoma Research, 2024
- DOI for The role of dacarbazine and temozolomide therapy after treatment with immune checkpoint inhibitors in malignant melanoma patients: A case series and meta-analysis
- Download full text (pdf) of The role of dacarbazine and temozolomide therapy after treatment with immune checkpoint inhibitors in malignant melanoma patients: A case series and meta-analysis
Part of Cancer Medicine, p. 13217-13224, 2023
- DOI for Predicting immune-related adverse events using a simplified frailty score in cancer patients treated with checkpoint inhibitors: A retrospective cohort study
- Download full text (pdf) of Predicting immune-related adverse events using a simplified frailty score in cancer patients treated with checkpoint inhibitors: A retrospective cohort study